Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

Anaplastic lymphoma kinase fusion gene-positive (ALK+) disease occurs in approximately 5% of patients with advanced non-small-cell lung cancer (NSCLC) [1]. Current standard first-line therapy for patients with advanced stage ALK+ NSCLC is an ALK inhibitor, such as crizotinib, ceritinib, brigatinib, or alectinib [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research